HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ROIV
Roivant Sciences Ltd.
There isn't enough reported data to score ROIV yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ROIV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Strong |
ROIV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ROIV PE Valuation
ROIV has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ROIV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ROIV's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ROIV on earnings, with more consistent year-over-year improvement.
ROIV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | -$0.02 |
| Q2 2026 | -$0.47 | +$0.22 |
| Q1 2026 | -$0.54 | -$0.30 |
| Q4 2025 | -$1.16 | -$1.02 |
| Q3 2025 | -$0.55 | -110% |
| Q2 2025 | -$0.69 | -112% |
| Q1 2025 | -$0.24 | -105% |
| Q4 2024 | -$0.14 | -103% |
ROIV is still losing money, but far less than before: $0.57 per share over the past year, against $1.55 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ROIV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ROIV on profitability, with a higher operating margin.
ROIV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +2136% |
| Q2 2026 | $1.4M | -34% |
| Q1 2026 | $2.5M | -67% |
| Q4 2025 | $2M | -78% |
| Q3 2025 | $1.6M | -65% |
| Q2 2025 | $2.2M | -96% |
| Q1 2025 | $7.6M | -74% |
| Q4 2024 | $9M | -76% |
ROIV's revenue is recovering but still below its 2024 peak: $35M last quarter, up 2136% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -763% | +18730 points |
| Q2 2026 | -25381% | -12251 points |
| Q1 2026 | 16478% | +20242 points |
| Q4 2025 | -16966% | -13924 points |
| Q3 2025 | -19493% | -11857 points |
| Q2 2025 | -13130% | -12912 points |
| Q1 2025 | -3764% | -2845 points |
| Q4 2024 | -3043% | -16669 points |
ROIV's operating margin was −763% last quarter, up 18730 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ROIV on cash generation, producing positive trailing cash flow while its opponent burns cash.
ROIV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $594.2M | +$787.7M |
| Q2 2026 | -$270.9M | -$62.5M |
| Q1 2026 | -$165.1M | +$8.3M |
| Q4 2025 | -$191.5M | +$17.5M |
| Q3 2025 | -$193.5M | +$74.3M |
| Q2 2025 | -$208.4M | -$14.6M |
| Q1 2025 | -$173.4M | -$64.6M |
| Q4 2024 | -$209.1M | +$1.7M |
ROIV has burned cash in almost every quarter: −$33M over the past year, against −$784M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ROIV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ROIV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2M shares |
| 1 year | +6.1% | +41.8M shares |
| 3 years | -6.2% | -47.5M shares |
| 5 years | +11% | +72.5M shares |
ROIV has 723M diluted shares, up 6.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $74.5M |
| Q2 2026 | $206.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $208.3M |
| Q1 2025 | $295.4M |
| Q4 2024 | $243.3M |
| Q3 2024 | $106.1M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ROIV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
ROIV has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ROIV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 60.6 | Neutral |
ROIV's weekly RSI is 65 (neutral) and its Stochastic is 61 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ROIV PE vs Healthcare Sector
| Metric | ROIV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ROIV has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ROIV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 9.3% above |
| 20 week MA | $36.3 | 10% above |
| 50 week MA | $30.6 | 31% above |
| 100 week MA | $21.6 | 85% above |
| 200 week MA | $16.0 | 149% above |
ROIV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ROIV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $10.1 | +1.8% |
| 2021 | $10.1 | $12.0 | +18% |
| 2022 | $12.0 | $7.01 | -41% |
| 2023 | $7.01 | $11.2 | +60% |
| 2024 | $11.2 | $11.8 | +5.1% |
| 2025 | $11.8 | $22.2 | +88% |
| 2026 YTD | $22.2 | $40.0 | +80% |
ROIV has the edge over HIMS on returns for 2026, with the stronger performance.